NCT01946438View on ClinicalTrials.gov

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

July 31, 2014

Conditions
Influenza
Interventions
BIOLOGICAL

Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),

0.5 mL, Intramuscular

BIOLOGICAL

Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),

0.1 mL, Intradermal

BIOLOGICAL

Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),

0.5 mL, Intramuscular

BIOLOGICAL

Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)

0.5 mL, Intramuscular

Trial Locations (4)

45249

Cincinnati

51503

Council Bluffs

70006

Metairie

95405

Santa Rosa

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT01946438 - Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults | Biotech Hunter | Biotech Hunter